Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSABD0)

Drug Name
TTNPB Drug Info
Synonyms
Arotinoid acid; 71441-28-6; Arotinoic acid; Ro 13-7410; CCRIS 3297; UNII-673M8C29UR; 4-[(E)-2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid; Tocris-0761; Lopac-T-3757; TTNPB (Arotinoid Acid); BRN 2008247; CHEMBL275311; CHEBI:75261; 673M8C29UR; 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid; (E)-4-(2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propen-1-yl)benzoic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5289501
ChEBI ID
CHEMBL275311
CAS Number
CAS 71441-28-6
TTD Drug ID
DMSABD0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Retinoic acid receptor beta (RARB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [10]
Tamibarotene DM3G74J T-cell leukaemia 2A90 Phase 3 [11]
PMID27336223-Compound-10 DMYUP6G N. A. N. A. Patented [12]
PMID27336223-Compound-8 DM460D1 N. A. N. A. Patented [12]
PMID27336223-Compound-7 DM9QM6I N. A. N. A. Patented [12]
CD666 DMC8X9Y Discovery agent N.A. Investigative [13]
AGN193109 DMC0YOE Discovery agent N.A. Investigative [14]
AC55649 DM4JNY9 Discovery agent N.A. Investigative [15]
BMS641 DMRT7G3 Discovery agent N.A. Investigative [16]
AC261066 DMSKE1I Discovery agent N.A. Investigative [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Involucrin (IVL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Calcipotriol DM03CP7 Psoriasis EA90 Approved [17]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [18]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [19]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [20]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [21]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [17]
Ursodeoxycholic acid DMCUT21 Cholelithiasis DC11 Approved [22]
Demecolcine DMCZQGK Solid tumour/cancer 2A00-2F9Z Approved [23]
Hydrocortisone DMGEMB7 Acne vulgaris ED80 Approved [24]
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Keratin, type I cytoskeletal 13 (KRT13)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [25]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [26]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [27]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [20]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [28]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [29]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [30]
Paclitaxel DMLB81S Breast carcinoma Approved [31]
Afimoxifene DMFORDT Breast cancer 2C60-2C65 Phase 2 [32]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Keratin, type II cytoskeletal 5 (KRT5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [26]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [34]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [34]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [35]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [36]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [37]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [38]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [39]
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [34]
Bexarotene DMOBIKY Cutaneous T-cell lymphoma 2B01 Approved [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Protein-glutamine gamma-glutamyltransferase 2 (TGM2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [18]
Etretinate DM2CZFA Keratosis ED56 Approved [40]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [9]
Testosterone DM7HUNW Hot flushes GA30 Approved [41]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [41]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [42]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [38]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [39]
Ethanol DMDRQZU Chronic pain MG30 Approved [43]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Stearoyl-CoA desaturase (SCD)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clavulanate DM2FGRT Bacteremia 1A73 Approved [45]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [46]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [46]
Methotrexate DM2TEOL Anterior urethra cancer Approved [47]
Quercetin DM3NC4M Obesity 5B81 Approved [48]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [49]
Fluoxetine DM3PD2C Bipolar depression Approved [46]
Fructose DM43AN2 Vomiting MD90 Approved [50]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [51]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Retinoblastoma-associated protein (RB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Indomethacin DMSC4A7 Bursitis Approved [52]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [53]
Gefitinib DM15F0X Colon adenocarcinoma Approved [54]
Talazoparib DM1KS78 Breast cancer 2C60-2C65 Approved [55]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [56]
Trametinib DM2JGQ3 Melanoma 2C30 Approved [57]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [58]
Methotrexate DM2TEOL Anterior urethra cancer Approved [59]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [60]
Quercetin DM3NC4M Obesity 5B81 Approved [61]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By G1/S-specific cyclin-D3 (CCND3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [62]
Gefitinib DM15F0X Colon adenocarcinoma Approved [63]
Quercetin DM3NC4M Obesity 5B81 Approved [61]
Furazolidone DM3P6V7 Diarrhea ME05.1 Approved [64]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [65]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [66]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [67]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [68]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [69]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [70]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cyclin-dependent kinase inhibitor 1B (CDKN1B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [53]
Gefitinib DM15F0X Colon adenocarcinoma Approved [63]
Prednisone DM2HG4X Acute asthma CA23 Approved [71]
Methotrexate DM2TEOL Anterior urethra cancer Approved [72]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [73]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [74]
Quercetin DM3NC4M Obesity 5B81 Approved [75]
Fluoxetine DM3PD2C Bipolar depression Approved [76]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [77]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [78]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Neural retina-specific leucine zipper protein (NRL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gefitinib DM15F0X Colon adenocarcinoma Approved [79]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [8]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [80]
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [8]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [81]
Urethane DM7NSI0 N. A. N. A. Phase 4 [82]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [83]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [84]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [85]
⏷ Show the Full List of 9 Drug(s)
Drug(s) Affected By Bile acid receptor (NR1H4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [86]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [87]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [88]
Quercetin DM3NC4M Obesity 5B81 Approved [48]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [3]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [89]
Nisoldipine DM7ISKJ Hypertension BA00-BA04 Approved [87]
Cholic Acid DM7OKQV Cholelithiasis DC11 Approved [88]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [90]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [91]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 4F11 (CYP4F11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [48]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [92]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [5]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [68]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [36]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [91]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [38]
Ethanol DMDRQZU Chronic pain MG30 Approved [93]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [94]
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Retinoic acid receptor beta (RARB) TTISP28 RARB_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Gene/Protein Processing [3]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Protein Interaction/Cellular Processes [4]
Cytochrome P450 4F11 (CYP4F11) OTHZ2GG2 CP4FB_HUMAN Gene/Protein Processing [5]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Gene/Protein Processing [6]
Involucrin (IVL) OT4VPNGY INVO_HUMAN Gene/Protein Processing [7]
Keratin, type I cytoskeletal 13 (KRT13) OTTYSKGX K1C13_HUMAN Gene/Protein Processing [7]
Keratin, type II cytoskeletal 5 (KRT5) OTVGI9HT K2C5_HUMAN Gene/Protein Processing [7]
Neural retina-specific leucine zipper protein (NRL) OT65MFKQ NRL_HUMAN Gene/Protein Processing [8]
Protein-glutamine gamma-glutamyltransferase 2 (TGM2) OT6MFOWF TGM2_HUMAN Gene/Protein Processing [9]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Post-Translational Modifications [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2646).
2 9-cis-retinoic acid analogues with bulky hydrophobic rings: new RXR-selective agonists. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6117-22.
3 The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution. Am J Physiol Regul Integr Comp Physiol. 2007 Sep;293(3):R1400-9. doi: 10.1152/ajpregu.00781.2006. Epub 2007 Jun 13.
4 Retinoids inhibit proliferation of human coronary smooth muscle cells by modulating cell cycle regulators. Arterioscler Thromb Vasc Biol. 2001 May;21(5):746-51. doi: 10.1161/01.atv.21.5.746.
5 Gene regulation of CYP4F11 in human keratinocyte HaCaT cells. Drug Metab Dispos. 2010 Jan;38(1):100-7. doi: 10.1124/dmd.109.029025.
6 Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade. Breast Cancer Res Treat. 2006 Mar;96(2):147-57. doi: 10.1007/s10549-005-9071-1. Epub 2005 Nov 5.
7 Retinoic acid receptor- and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells. Cell Growth Differ. 1996 Aug;7(8):997-1004.
8 Retinoic acid regulates the expression of photoreceptor transcription factor NRL. J Biol Chem. 2006 Sep 15;281(37):27327-34. doi: 10.1074/jbc.M605500200. Epub 2006 Jul 19.
9 TCDD suppression of tissue transglutaminase stimulation by retinoids in malignant human keratinocytes. Toxicol Sci. 2000 Aug;56(2):357-64.
10 Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4.
11 Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12.
12 Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71.
13 Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun. 1992 Jul 31;186(2):977-83.
14 Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000 Jan;6(1):25-58.
15 Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist. J Med Chem. 2005 Dec 1;48(24):7517-9.
16 Rational design of RAR-selective ligands revealed by RARbeta crystal stucture. EMBO Rep. 2004 Sep;5(9):877-82.
17 Effects of 1 alpha,25-dihydroxy-vitamin D3 and calcipotriol on organotypic cultures of outer root sheath cells: a potential model to evaluate antipsoriatic drugs. Arch Dermatol Res. 1993;285(7):402-9. doi: 10.1007/BF00372133.
18 Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
19 Retinoic acid receptors as regulators of human epidermal keratinocyte differentiation. Mol Endocrinol. 1992 May;6(5):667-76. doi: 10.1210/mend.6.5.1318502.
20 Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
21 Retinoic acid and hydroquinone induce inverse expression patterns on cornified envelope-associated proteins: implication in skin irritation. J Dermatol Sci. 2014 Nov;76(2):112-9. doi: 10.1016/j.jdermsci.2014.08.003. Epub 2014 Aug 26.
22 Correlation of chemopreventive efficacy data from the human epidermal cell assay with in vivo data. Anticancer Res. 2000 Jan-Feb;20(1A):27-32.
23 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
24 Deducing signaling pathways from parallel actions of arsenite and antimonite in human epidermal keratinocytes. Sci Rep. 2020 Feb 19;10(1):2890. doi: 10.1038/s41598-020-59577-0.
25 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
26 Activation of PPAR and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells. PLoS One. 2020 Aug 21;15(8):e0237976. doi: 10.1371/journal.pone.0237976. eCollection 2020.
27 Retinoic acid-induced glandular differentiation of the oesophagus. Gut. 2007 Jul;56(7):906-17. doi: 10.1136/gut.2006.097915. Epub 2006 Dec 21.
28 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
29 Extremely low copper concentrations affect gene expression profiles of human prostate epithelial cell lines. Chem Biol Interact. 2010 Oct 6;188(1):214-9.
30 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
31 cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat. 2006 Mar;96(1):17-39. doi: 10.1007/s10549-005-9026-6. Epub 2005 Dec 2.
32 Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res. 2006 Jul 15;66(14):7334-40.
33 CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
34 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
35 Oral lichenoid eruption secondary to imatinib (Glivec). J Dermatolog Treat. 2004 Jul;15(4):253-5. doi: 10.1080/09546630410015556.
36 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
37 Evaluation of a human iPSC-derived BBB model for repeated dose toxicity testing with cyclosporine A as model compound. Toxicol In Vitro. 2021 Jun;73:105112. doi: 10.1016/j.tiv.2021.105112. Epub 2021 Feb 22.
38 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
39 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
40 Gene-specific TCDD suppression of RARalpha- and RXR-mediated induction of tissue transglutaminase. Toxicol Sci. 2002 Jul;68(1):102-8. doi: 10.1093/toxsci/68.1.102.
41 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
42 Inter-laboratory comparison of human renal proximal tubule (HK-2) transcriptome alterations due to Cyclosporine A exposure and medium exhaustion. Toxicol In Vitro. 2009 Apr;23(3):486-99.
43 NF-kappaB-activated tissue transglutaminase is involved in ethanol-induced hepatic injury and the possible role of propolis in preventing fibrogenesis. Toxicology. 2008 Apr 18;246(2-3):148-57.
44 PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells. J Exp Med. 2006 Oct 2;203(10):2351-62.
45 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
46 Antidepressant drugs activate SREBP and up-regulate cholesterol and fatty acid biosynthesis in human glial cells. Neurosci Lett. 2006 Mar 13;395(3):185-90. doi: 10.1016/j.neulet.2005.10.096. Epub 2005 Dec 1.
47 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
48 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
49 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
50 Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 2008 Feb;34(1):82-5. doi: 10.1016/j.diabet.2007.08.004. Epub 2007 Dec 11.
51 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
52 Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase. Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. doi: 10.3181/0804-RM-127. Epub 2008 Sep 12.
53 Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Apr 28;18(3):333-45. doi: 10.1530/ERC-10-0262. Print 2011 Jun.
54 Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
55 BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
56 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
57 Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
58 Sulindac induces specific degradation of the HPV oncoprotein E7 and causes growth arrest and apoptosis in cervical carcinoma cells. Cancer Lett. 2007 Jan 8;245(1-2):103-11. doi: 10.1016/j.canlet.2005.12.034. Epub 2006 Feb 20.
59 Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance. Exp Cell Res. 2012 Jun 10;318(10):1146-59.
60 HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects. J Pharmacol Exp Ther. 2008 Jan;324(1):352-9. doi: 10.1124/jpet.107.128959. Epub 2007 Oct 10.
61 Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004 Jan;11(1):63-9. doi: 10.1128/cdli.11.1.63-69.2004.
62 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
63 Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 2006 Jun 1;66(11):5542-8. doi: 10.1158/0008-5472.CAN-05-4620.
64 Involvement of the p38 MAPK signaling pathway in S-phase cell-cycle arrest induced by Furazolidone in human hepatoma G2 cells. J Appl Toxicol. 2013 Dec;33(12):1500-5. doi: 10.1002/jat.2829. Epub 2012 Oct 30.
65 Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism. Diabetologia. 2005 Mar;48(3):586-94. doi: 10.1007/s00125-005-1672-z. Epub 2005 Feb 24.
66 Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms. Cancer Res. 2005 Jul 15;65(14):6476-83. doi: 10.1158/0008-5472.CAN-05-0370.
67 Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
68 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
69 DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 Jul;25(7):1293-8.
70 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
71 Glucocorticoids induce G1 arrest of lymphoblastic cells through retinoblastoma protein Rb1 dephosphorylation in childhood acute lymphoblastic leukemia in vivo. Cancer Biol Ther. 2004 May;3(5):470-6. doi: 10.4161/cbt.3.5.838. Epub 2004 May 9.
72 Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. Arthritis Rheum. 2012 Jun;64(6):1780-9. doi: 10.1002/art.34342. Epub 2011 Dec 19.
73 Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells. Melanoma Res. 2008 Apr;18(2):85-94. doi: 10.1097/CMR.0b013e3282f60097.
74 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
75 Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001 May 15;61(10):1205-15. doi: 10.1016/s0006-2952(01)00583-4.
76 Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol. 2008 May 15;75(10):1924-34. doi: 10.1016/j.bcp.2008.02.013. Epub 2008 Feb 17.
77 Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 2003 Jan-Feb;23(1A):267-73.
78 Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol. 2007 Feb;4(1):59-63.
79 Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer. Oncol Rep. 2006 Jun;15(6):1453-60.
80 Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. Drug Metab Pharmacokinet. 2014;29(4):333-40.
81 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
82 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
83 Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.
84 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
85 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
86 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
87 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
88 Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
89 Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
90 Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol. 2012 Jun 15;83(12):1674-81. doi: 10.1016/j.bcp.2012.02.027. Epub 2012 Mar 7.
91 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
92 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
93 CYP4F2 repression and a modified alpha-tocopherol (vitamin E) metabolism are two independent consequences of ethanol toxicity in human hepatocytes. Toxicol In Vitro. 2017 Apr;40:124-133.
94 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.